Back to top

gene-editing: Archive

Ahan Chakraborty

Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?

Despite the recent pipeline setback, investors are encouraged to buy the FULC stock based on the potential of its promising SCD candidate, pociredir.

VRTXPositive Net Change BLUENegative Net Change CRSPPositive Net Change FULCPositive Net Change

Zacks Equity Research

RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag

Ultragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta treatment candidate, setrusumab.

ALNYPositive Net Change CPRXPositive Net Change ANIPPositive Net Change RAREPositive Net Change